Forest urges investors to reject Icahn's board nominees

The latest on Forest Laboratories' ($FRX) defense against activist investor Carl Icahn: The drugmaker called on shareholders to ignore Icahn's four board nominees. Icahn has accused Forest officials, including CEO Howard Solomon, of mismanaging the company and enriching themselves "to the detriment of the stockholders." Report